- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06807281
2 세 이상의 어린이에서 아edcocitinib라는 약에 대한 장기 연구
아크리 티 닙의 안전성과 효능을 평가하는 3 단계, 다기관, 장기, 오픈 라벨 연구, 2 세 이상의 소아 참가자에게 시행되는 국소 약물이 있거나없는 약물 약물이 중등도에서 중등도의 아토피 성 피부염으로 투여됩니다.
This 24-month study will assess the long-term safety and efficacy of liquid abrocitinib oral suspension with or without topical medications in children 2 years of age or older with moderate-to-severe atopic dermatitis. The study will enroll two groups: participants who have completed other abrocitinib studies and participants who have never participated in abrocitinib studies.
연구 개요
상세 설명
Phase 3, open-label study to assess the long-term safety and efficacy of liquid abrocitinib oral suspension with or without topical medications in children ≥2 years of age with moderate-to-severe atopic dermatitis (AD). This study will enroll participants in two cohorts: an extension cohort of participants who previously completed prior abrocitinib studies, and a de novo cohort of participants (6 to <12 years of age) who have not participated in previous abrocitinib studies. Study duration will be up to 2 years (or commercial availability, whichever occurs earlier). The study will enroll a maximum of approximately 500 participants with moderate-to-severe Atopic Dermatitis from study sites globally (extension cohort will enroll up to 320 participants; de novo cohort will enroll approximately 180 participants). All participants will receive the study intervention abrocitinib oral suspension.
연구 유형
등록 (추정된)
단계
- 3단계
연락처 및 위치
연구 연락처
- 이름: Pfizer CT.gov Call Center
- 전화번호: 1-800-718-1021
- 이메일: ClinicalTrials.gov_Inquiries@pfizer.com
연구 장소
-
-
-
Chihuahua City, 멕시코, 31238
- 아직 모집하지 않음
- Servicios Hospitalarios de Mexico S.A. DE C.V.
-
-
Mexico City
-
Mexico City, Mexico City, 멕시코, 06720
- 아직 모집하지 않음
- Hospital Infantil de Mexico Federico Gomez
-
-
Nuevo León
-
Monterrey, Nuevo León, 멕시코, 64718
- 아직 모집하지 않음
- Eukarya Pharmasite S.C.
-
-
Veracruz Ignacio de LA Llave
-
Veracruz, Veracruz Ignacio de LA Llave, 멕시코, 91900
- 아직 모집하지 않음
- Arké SMO S.A de C.V
-
-
-
-
Alabama
-
Birmingham, Alabama, 미국, 35244
- 모병
- Cahaba Dermatology & Skin Health Center
-
-
Arkansas
-
North Little Rock, Arkansas, 미국, 72117
- 모병
- Arkansas Research Trials
-
-
California
-
San Diego, California, 미국, 92123
- 모병
- Investigational Drug Service - Rady Childrens Hospital-San Diego
-
San Diego, California, 미국, 92123
- 모병
- University of California, San Diego/ Rady Children's Hospital - San Diego
-
-
Florida
-
Jacksonville, Florida, 미국, 32256
- 모병
- Solutions Through Advanced Research
-
-
Idaho
-
Meridian, Idaho, 미국, 83646
- 모병
- Ada West Research - Meridian
-
-
Indiana
-
Indianapolis, Indiana, 미국, 46250
- 모병
- Dawes Fretzin Clinical Research Group, LLC
-
-
Missouri
-
St Louis, Missouri, 미국, 63104
- 모병
- Saint Louis University
-
-
South Carolina
-
Charleston, South Carolina, 미국, 29425
- 모병
- Medical University of South Carolina - South Carolina Translational Research Nexus Clinic
-
Greenville, South Carolina, 미국, 29607
- 모병
- Tribe Clinical Research, LLC
-
-
Texas
-
San Antonio, Texas, 미국, 78235
- 모병
- Texas Dermatology and Laser Specialists
-
-
-
-
-
Zaragoza, 스페인, 50009
- 모병
- Hospital Universitario Miguel Servet
-
-
A Coruña [LA Coruña]
-
Santiago de Compostela, A Coruña [LA Coruña], 스페인, 15706
- 모병
- CHUS - Hospital Clinico Universitario
-
-
Barcelona
-
Granollers, Barcelona, 스페인, 08402
- 모병
- Hospital General de Granollers
-
-
-
-
-
Fukuoka, 일본, 811-1394
- 모병
- Fukuoka National Hospital
-
Fukuoka, 일본, 819-0042
- 모병
- Saruta Dermatology Clinic
-
-
Kanagawa
-
Yokohama, Kanagawa, 일본, 220-6208
- 모병
- Queen's square Medical Facilities Queen's square Dermatology and Allergology
-
-
Osaka
-
Sakai, Osaka, 일본, 593-8324
- 모병
- Dermatology and Ophthalmology Kume Clinic
-
-
Tokyo
-
Setagaya-ku, Tokyo, 일본, 157-0066
- 모병
- Sasamoto Children's Clinic
-
-
-
-
-
Shanghai, 중국, 200062
- 모병
- Shanghai Children's Hospital
-
Shanghai, 중국, 200092
- 모병
- Xinhua Hospital Affiliated to Shanghai JiaoTong University School of Medicine
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, 중국, 100045
- 모병
- Beijing Children's hospital, Capital Medical University
-
-
Guangdong
-
Shenzhen, Guangdong, 중국, 518026
- 모병
- Shenzhen Children's Hospital
-
-
Hunan
-
Changsha, Hunan, 중국, 410007
- 모병
- Hunan Children's Hospital
-
-
Jiangxi
-
Nanchang, Jiangxi, 중국, 330000
- 아직 모집하지 않음
- Dermatology Hospital of Jiangxi Province
-
-
Zhejiang
-
Hangzhou, Zhejiang, 중국, 310009
- 모병
- Hangzhou Third People's Hospital
-
-
-
-
Lesser Poland Voivodeship
-
Krakow, Lesser Poland Voivodeship, 폴란드, 30-002
- 모병
- Specjalistyczny Gabinet Dermatologiczny Aplikacyjno-Badawczy, Marek Brzewski, Paweł Brzewski spółka cywilna
-
-
Lublin Voivodeship
-
Lublin, Lublin Voivodeship, 폴란드, 20-573
- 모병
- LUXDERM Specjalistyczny Gabinet Dermatologiczny prof. dr hab. n. med. Dorota Krasowska
-
-
Masovian Voivodeship
-
Warsaw, Masovian Voivodeship, 폴란드, 02-625
- 모병
- Centrum Medyczne Evimed
-
-
Silesian Voivodeship
-
Chorzów, Silesian Voivodeship, 폴란드, 41-500
- 모병
- DERMAPOLIS Medical Dermatology Center dr n. med. Edyta Gebska
-
-
Łódź Voivodeship
-
Lodz, Łódź Voivodeship, 폴란드, 90-436
- 모병
- Dermoklinika - Centrum Medyczne spółka cywilna M. Kierstan, J. Narbutt, A. Lesiak
-
-
Świętokrzyskie Voivodeship
-
Ostrowiec Świętokrzyski, Świętokrzyskie Voivodeship, 폴란드, 27-400
- 모병
- Dermedic Jacek Zdybski
-
-
-
-
Baranya
-
Pécs, Baranya, 헝가리, 7632
- 모병
- Pécsi Tudományegyetem Klinikai Központ
-
-
Bekes County
-
Békéscsaba, Bekes County, 헝가리, 5600
- 모병
- Trial Pharma Kft.
-
-
Csongrád-csanád
-
Szeged, Csongrád-csanád, 헝가리, 6720
- 아직 모집하지 않음
- University of Szeged
-
-
Pest County
-
Budapest, Pest County, 헝가리, 1033
- 모병
- Clinexpert Kft.
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria for the Extension Cohort:
1. Participants who have completed the treatment phase of the qualifying parent study (age 2 to <12 years old).
• No contraception methods are required for male participants. Female participants must not be pregnant or breastfeeding and, if the participant is of child-bearing potential, must use a highly effective form of contraception (i.e., abstinence) during the study intervention period and for at least 28 days after the last dose of study intervention.
Inclusion Criteria for the De Novo Cohort:
Age
-
Children aged 6 to <12 years at the time of informed consent/assent.
• No contraception methods are required for male participants.
Disease Characteristics:
-
Participants who meet all of the following AD criteria:
- A documented diagnosis of chronic AD for at least 6 months prior to screening and confirmed at screening and baseline visits according to the Hanifin and Rajka criteria; and
- A diagnosis of moderate-to-severe AD at the baseline visit (must fulfill all of the following criteria: BSA ≥10%, vIGA ≥3, EASI ≥16, and WI-NRS ≥4); and
- Documented history (within 6 months of the screening visit) of inadequate response to treatment with topical medical therapy for AD (eg, TCS and TCI), for at least 4 weeks and are candidates for systemic therapy.
Other Inclusion Criteria:
-
Body weight ≥15 kg
Exclusion Criteria for the Extension Cohort:
Medical Conditions:
-
Any medical or psychiatric condition including any active suicidal ideation in the past year or suicidal behavior in the past 5 years or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
If the participant has SDQ total score ≥17, the investigator should exclude the child or refer them to a pediatric MHP to determine if it is safe to participate in the study. A copy or summary of the evaluation should be placed in the site source documents.
Prior/Concomitant Therapy:
-
Required use of any prohibited concomitant treatments outlined in Section 6.9.3 and Appendix 9 of study protocol.
-
Required vaccination with live attenuated vaccines during study treatment and for 6 weeks after discontinuing study treatment.
Diagnostic Assessments:
-
Ongoing adverse event in the parent studies which in the opinion of the investigator, or sponsor, is an ongoing safety concern OR the participant is currently triggering safety monitoring criteria.
-
Discontinued from treatment early in the parent studies OR triggered a discontinuation criterion at any point during the parent studies OR meets exclusion criteria from the parent studies which in the opinion of the investigator, or sponsor, is an ongoing safety concern.
Exclusion Criteria for the De Novo Cohort
Medical Conditions:
-
Any medical or psychiatric condition including any active suicidal ideation in the past year or suicidal behavior in the past 5 years or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
If the participant has SDQ total score ≥17, the investigator should exclude them or refer the child to a pediatric MHP to determine if it is safe to participate in the study. A copy or summary of the evaluation should be placed in the site source documents.
-
Have any of the following medical conditions:
-
Infections:
- Skin infections that require treatment with systemic antimicrobials within 2 weeks prior to Day 1 (baseline) or have superficial skin infections within 1 week of Day 1.
- History of systemic infection requiring hospitalization or parenteral antimicrobial therapy or as otherwise judged clinically significant by the investigator within 1 month prior to Day 1.
- Have a history (single episode) of disseminated herpes zoster or disseminated herpes simplex, or a recurrent localized, dermatomal herpes zoster.
- Infection with HIV, hepatitis B, and/or hepatitis C
- Evidence of active TB or inadequately treated latent TB.
-
Skin Conditions:
- Including but not limited to psoriasis, seborrheic dermatitis or lupus on Day 1 that would interfere with evaluation of AD or response to treatment.
-
Other Conditions:
- Documented history of skeletal dysplasia.
- Documented history of retinal detachment.
- History of or conditions associated with thrombocytopenia, coagulopathy or platelet dysfunction.
- Prior history of leukemia, lymphoma, sarcoma or any other malignancy.
- Immunodeficiency disorder or a first-degree relative with a hereditary immunodeficiency.
- Any other medical conditions that in the investigator's judgment make the participant inappropriate for the study.
Prior/Concomitant Therapy:
-
-
Prior treatment with a systemic JAK inhibitor for AD.
-
Live attenuated vaccination within 6 weeks prior to Day 1 or require vaccination with live attenuated vaccines during treatment or within 6 weeks after the last dose of study intervention.
-
Concomitant use of strong inhibitors and inducers of CYP2C19 enzymes and strong inducers of CYP2C9 enzymes is not allowed in the study.
Prior/Concurrent Clinical Study Experience:
-
Previous administration of an investigational drug within 30 days or 5 half lives, whichever is longer, of Day 1.
Diagnostic Assessments:
-
Hepatic and/or renal and/or hematological abnormalities defined as:
- AST >2 x ULN
- Hemoglobin <10 g/dL
- ALT >2 x ULN
- ANC <1000/mm3
- Total bilirubin ≥1.5 x ULN
- ALC <500/mm3
- eGFR <60 mL/min/1.73 m2
- Platelets <150,000 /mm3
Other Exclusion Criteria:
-
Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Extension
Patients who have completed other abrocitinib studies |
Abrocitinib administered as liquid oral suspension.
다른 이름들:
|
|
실험적: De novo
Patients who have not participated other abrocitinib studies |
Abrocitinib administered as liquid oral suspension.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Number of Participants with Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and adverse events (AEs) that lead to study discontinuation
기간: 0-24 months
|
The number of the treatment emergent adverse events, serious adverse events and adverse events leading to discontinuation among patients with moderate-to-severe disease treated with abrocitinib regardless of discontinuation from study treatment. |
0-24 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Number of Participants With Clinically Significant Laboratory Abnormalities
기간: 0-24 months
|
The number of clinically significant laboratory abnormalities among participants with moderate-to-severe disease treated with abrocitinib. |
0-24 months
|
|
Response based on achieving Validated Investigator's Global Assessment (vIGA) score of clear (0) or almost clear (1) (on a 5-point scale) and a 2 -point reduction from baseline at all scheduled time points
기간: Baseline, 24 months
|
Proportion of responders based on vIGA at all scheduled time points in patients with moderate-to-severe disease treated with abrocitinib |
Baseline, 24 months
|
|
Percentage of Response based on achieving a ≥4 point improvement from baseline in the Worst Itch Numerical Rating Scale (WI-NRS) at all scheduled time points in participants aged ≥2 to <6 years
기간: 0-24 months
|
Percentage of responders based on achieving an improvement ≥4 points from baseline at all scheduled time points in the WI-NRS (in patients aged ≥2 to <6 years) with moderate-to-severe disease treated with abrocitinib. |
0-24 months
|
|
Percentage of Response based on achieving a ≥4-point improvement from baseline in the WSI-NRS at all scheduled time points in participants aged ≥6 to 12 years
기간: 0-24 months
|
Percentage of responders based on achieving an improvement ≥4 points from baseline at all scheduled time points in the WSI-NRS (in patients aged ≥6 to 12 years) with moderate-to-severe disease treated with abrocitinib. |
0-24 months
|
|
Percentage of Responders based on achieving Eczema Area and Severity Index (EASI)-50, EASI-90 and EASI-100 at all scheduled time points in participants with moderate-to-severe disease treated with abrocitinib
기간: 0-24 months
|
Percentage of response based on achieving ≥50%, ≥90%, 100% improvement from parent study baseline in the EASI total score (EASI-50, EASI-90, EASI-100) at all scheduled time points. |
0-24 months
|
|
Percent Change from Baseline (CFB) in EASI total score at all scheduled time points.
기간: 0-24 months
|
Mean percent CFB in EASI total score at all scheduled time points in patients with moderate-to-severe disease treated with abrocitinib |
0-24 months
|
|
Percentage of Participants with Flares
기간: 0-24 months
|
Percentage of participants reporting flares in patients with moderate-to-severe disease treated with abrocitinib. |
0-24 months
|
|
CFB in the percentage Body Surface Area (BSA) affected at all scheduled time points
기간: 0-24 months
|
Mean CFB in BSA affected at all scheduled time points in patients with moderate-to-severe disease treated with abrocitinib. |
0-24 months
|
|
CFB in Children's Dermatology Life Quality Index (CDLQI) at all scheduled time points.
기간: 0-24 months
|
Mean CFB in CDLQI at all scheduled time points in participants aged ≥4 to <16 years with moderate-to-severe disease treated with abrocitinib. |
0-24 months
|
|
CFB in in Infants' Dermatitis Quality of Life (IDQOL) Index at all scheduled time points
기간: 0-24 months
|
Mean CFB in IDQOL Index or CDQLI depending on age at all scheduled time points in participants aged <4 years with moderate-to-severe disease treated with abrocitinib |
0-24 months
|
|
CFB in Patient-Oriented Eczema Measure (POEM) at all scheduled time points
기간: 0-24 months
|
Mean CFB in POEM at all scheduled time points in participants with moderate-to-severe disease treated with abrocitinib. |
0-24 months
|
|
CFB in Dermatitis Family Impact (DFI) at all scheduled time points
기간: 0-24 months
|
Mean CFB in DFI at all scheduled time points in participants with moderate-to-severe disease treated with abrocitinib. |
0-24 months
|
|
CFB in Patient Global Impression of Severity (PGIS) at all scheduled time points
기간: 0-24 months
|
Mean CFB in PGIS (in patients aged 6 to <12 years) at all scheduled time points in patients with moderate-to-severe disease treated with abrocitinib. |
0-24 months
|
|
CFB in Observer Reported Global Impression of Severity (OGIS) at all scheduled time points
기간: 0-24 months
|
Mean CFB in OGIS (in patients aged 2 to <6 years) at all scheduled time points in patients with moderate-to-severe disease treated with abrocitinib |
0-24 months
|
|
CFB in the the EuroQol- 5 Dimension Youth (EQ-5D-Y)
기간: 0-24 months
|
Mean CFB in EQ-5D-Y at all scheduled time points in patients with moderate-tosevere AD treated with abrocitinib versus placebo. |
0-24 months
|
|
Number of topical corticosteroid and /or topical calcineurin inhibitor free days
기간: 0-24 months
|
Mean number of days free from topical corticosteroids and /or topical calcineurin inhibitor use in patients with moderate-to-severe disease treated with abrocitinib. |
0-24 months
|
|
Percentage of Participants Achieving satisfactory response in Tdap/DTaP and/or pneumococcal antibody titers as appropriate in participants who receive Tdap/DTaP and/or pneumococcal vaccinations
기간: 0-24 months
|
For patients that receive Tdap/ DTap and/or pneumococcal vaccinations during the study, the proportion of patients treated with abrocitinib who achieve satisfactory immunogenicity at 4 weeks after receiving the vaccinations. |
0-24 months
|
공동 작업자 및 조사자
스폰서
수사관
- 연구 책임자: Pfizer CT.gov Call Center, Pfizer
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- B7451031
- 2023-509124-18-00 (레지스트리 식별자: CTIS (EU))
- 2023 (미국 NIH 보조금/계약)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .